Other
Jul 2026Core products are still pre-clinical/clinical-stage and the website says they are not FDA/CE approved yet, so commercialization depends on trial and regulatory outcomes.
SourceWe make cancer care at home possible.
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Irish MedTech startup building technology-enabled oncology care services and wearable devices to reduce chemotherapy side effects and make some cancer care possible at home. Public sources vary on founding year (2018 vs. 2019); the company’s About page says 2019, while other public profiles cite 2018.
Primary product
Lotus Home Infusion platform
Founded
2019
Headquarters
Block 9, Ballybrit, Galway, H91 FW1H, Ireland
Team size
50-60
Work style
Hybrid
Industry
Medical Equipment Manufacturing
Sub-industry
MedTech / oncology supportive care and home infusion
Offices
Galway, Ireland
Chicago, Illinois, United States
San Antonio, Texas, United States
Omaha, Nebraska, United States
Business model
technology-enabled healthcare services
provider partnership model
payer partnership model
medical device development
Funding
Stage
Series A
Total raised
$50M
Latest round
Expanded Series A · Jan 2026
Latest amount
$21M
Jan 2026 · ARTIS Ventures and Lachy Groom
Third DTIF grant (reported €6.4M/€6.5M)
Apr 2025 · Irish Government DTIF
Sep 2024 · ARTIS Ventures
Second DTIF grant (€4.4M reported)
Jan 2023 · Irish Government DTIF
Jan 2022 · SciFounders, Elkstone, and Faber
Jan 2022 · Irish Government DTIF
Aug 2021 · Y Combinator
Jan 2019 · Enterprise Ireland
People & investors
Leadership
CEO and Co-Founder
CCO and Co-Founder
CSO and Co-Founder
Chief Financial Officer
VP R&D and Operations
Emmet Frawley
VP RA/QA
Cathy O'Boyle
Head of Healthcare Services
Work & culture
Mission-driven, patient-focused, and collaborative; the company describes its teams as engineers, designers, clinicians, and researchers working together to make cancer care more human.
Work style
Hybrid
Compensation
No public salary bands or compensation ranges found.
Product & market
Pricing
Not publicly disclosed; appears to rely on enterprise/provider and payer partnership contracts rather than public self-serve pricing.
Differentiators
- —Nurse-led at-home cancer treatment while maintaining drug dispensing with the originating provider
- —Integrated with oncology clinics, pharmacies, and payer workflows
- —Focuses on both side-effect prevention devices and home infusion services
- —Targets lower costs and lower patient burden without removing provider oversight
- —Clinical-stage platform spanning Lily, Lilac, and Lotus
Technology
BambooHR
SolidWorks
Medidata Rave
microservices
APIs
cloud-based systems
Customers
oncology clinics
health systems
health plans
oncology providers
Competitors
TriSalus Life Sciences
Delcath Systems
Embolx
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
6.5K
Signals & risks
Latest news
The Journal Gazette · Jun 2026
Covered Parkview Health’s participation in the Lilac/IMPACT trial and explained the device’s goal of preventing chemotherapy-induced peripheral neuropathy.
GlobeNewswire / ARTIS Ventures · Jan 2026
Announced a $21M expanded Series A, taking total funding to over $50M, with offices in Galway, Chicago, San Antonio, and Omaha and plans to expand home cancer care at 40 partner clinics.
The Irish Times · Jan 2026
Reported the same funding round and said Luminate planned to create 130 jobs.
Silicon Republic · Jan 2026
Covered the $21M raise, 130 planned jobs, and the Lotus home-cancer-care roadmap.
The Irish Times · Jun 2025
Profiled Luminate’s effort to move some cancer care into the home, framing the company’s products and strategy around lower burden and provider-controlled home treatment.
Jobs and careers at Luminate
2 jobs at Luminate
VP & Head of Legal
On-site
Luminate - Corporate / Administration
Los Angeles, CA; California - Los Angeles Office
3d ago
On-site
Full-time
Revenue Operations Manager
On-site
Luminate - Sales
Los Angeles, CA; California - Los Angeles Office
2w ago
On-site
Full-time